Logo

American Heart Association

  67
  0


Final ID: Wed123

Multiscale Analysis of the Role of Skeletal Muscle Actin Mutations in Causing Dilated Cardiomyopathy

Abstract Body: Skeletal muscle actin (ACTA1) is robustly expressed in skeletal muscle and expressed at lower levels in the heart. While ACTA1 mutations are known to cause skeletal myopathies, several case reports indicate that some ACTA1 mutations may also cause cardiomyopathy. We previously reported that R256H ACTA1 is associated with dilated cardiomyopathy without apparent skeletal myopathy. To establish a causative link between R256H ACTA1 and cardiomyopathy, we created an Acta1R256H/+ knockin mouse. These mice have no baseline cardiac defects consistent with the lack of Acta1 expression in healthy murine hearts. Intriguingly, Acta1 expression increases following cardiac injury and stress. Following transaortic constriction Acta1R256H/+ knockin mice display a heart failure phenotype. We analyze calcium-dependent force production of single skinned cardiomyocytes and found that despite the lack of baseline cardiac phenotype in Acta1R256H/+ mice, skinned isolated cardiomyocytes displayed decreased force production. Decreased force production was also observed in ACTA1R256H/+ human iPSC-derived cardiomyocytes. To dissect how ACTA1 mutations might cause contractile defects, we purified recombinant R256H ACTA1 and observed decreased stability (thermal shift assay) and polymerization (fluorescent actin polymerization) compared to WT ACTA1 protein. Importantly, we found that R256H ACTA1 acts in a dominant fashion where addition of a small amount of mutant protein to WT ACTA1 is sufficient to disrupt contractility (in vitro motility). To understand the structural changes responsible for this phenomenon, we resolved the structure of the R256H ACTA1 filament by cryo-EM. We find a disrupted interaction between ACTA1 K240 and tropomyosin E117, a residue important for maintaining tropomyosin in the open state to allow for molecular contractility. Collectively, we show that an ACTA1 mutation is capable of causing dilated cardiomyopathy, which may be related to multiple defects in actin function. Future studies will be required to decipher whether other ACTA1 mutations reduce contractility through similar mechanisms.
  • Garg, Ankit  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Greenberg, Michael  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Jansen, Silvia  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Meyer, Gretchen  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Greenberg, Lina  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Jani, Vivek  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Li, Fengying  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Kass, David  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Zhang, Rui  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Lavine, Kory  ( WASHINGTON UNIVERSITY SCHOOL OF MED , Saint Louis , Missouri , United States )
  • Author Disclosures:
    Ankit Garg: DO NOT have relevant financial relationships | Michael Greenberg: DO have relevant financial relationships ; Research Funding (PI or named investigator):Edgewise:Active (exists now) ; Consultant:Sanofi:Past (completed) | Silvia Jansen: No Answer | Gretchen Meyer: DO NOT have relevant financial relationships | Lina Greenberg: DO NOT have relevant financial relationships | Vivek Jani: DO NOT have relevant financial relationships | Fengying Li: DO NOT have relevant financial relationships | David Kass: DO have relevant financial relationships ; Advisor:Amgen:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Gordian:Active (exists now) ; Consultant:Alleviant:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Advisor:Cytokinetics:Active (exists now) ; Advisor:Cardurion:Active (exists now) | Rui Zhang: No Answer | Kory Lavine: DO have relevant financial relationships ; Advisor:Implicit biosciences:Active (exists now) ; Research Funding (PI or named investigator):Implicit Biosciences:Active (exists now) ; Research Funding (PI or named investigator):Bitterroot:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now)
Meeting Info:

Basic Cardiovascular Sciences 2025

2025

Baltimore, Maryland

Session Info:

Poster Session and Reception 1

Wednesday, 07/23/2025 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available